Pulmatrix, Inc. (PULM)
PULMNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.36
-0.0250 (-1.81%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $4.75m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.06 to $4.98
- Average volume
- 37.4k
- Previous close
- $1.38
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$866.0k | -$908.0k | -$1.29m | -$1.05m |
| Net income | -$877.0k | -$928.0k | -$1.17m | -$1.04m |
News
7 latest- Eos SENOLYTIX Reports Preserved Motor Function In Aged Rats With PTC-2105; Stock Down RTTNews · Oct 30, 2026
- Pulmatrix, Inc. Stockholders Approve Merger-Related Proposals and Reverse Stock SplitFintel · Oct 27, 2026
- Weekly Buzz: CORT Wins FDA Nod In Cancer; MRK Acquires TERN; INSM Meets Trial Goals But VALN Misses RTTNews · Mar 27, 2026
- Pulmatrix And Eos SENOLYTIX Announce Merger To Advance Mitochondrial Therapies; Stock Plunges RTTNews · Mar 26, 2026
- Pulmatrix To Acquire Eos Senolytix In Merger RTTNews · Mar 26, 2026
- Pulmatrix (PULM) Q2 Revenue Falls 100%The Motley Fool · Aug 6, 2025
- UniQure (QURE) Reports Q2 Loss, Misses Revenue EstimatesZacks · Aug 1, 2023
The company
Pulmatrix is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE technology. Pulmatrix's proprietary product pipeline includes treatments for central nervous system ('CNS') disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ('COPD') and allergic bronchopulmonary aspergillosis ('ABPA'). Pulmatrix's product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- pulmatrix.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.